Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of other drugs on axitinib intravitreal implant

4 evidence topics · 2 sources

Clinical drug interaction studies with the intravitreal implant

No evidence found.

Systemic exposure after intravitreal administration as context for interaction potential

“Plasma levels of the active drug, axitinib, were below the limit of quantification at all doses, indicating that systemic exposure to intravitreal delivery of axitinib by AXPAXLI up to 600 μg was negligible.” (opens the source at this quote in a new tab)

Class context: oral axitinib (INLYTA) with strong CYP3A4/5 inhibitors

“Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. Co-administration of INLYTA with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided.” (opens the source at this quote in a new tab)

Class context: oral axitinib (INLYTA) with strong CYP3A4/5 inducers

“Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers.” (opens the source at this quote in a new tab)

Class context: oral axitinib (INLYTA) pH-dependent solubility

“Additionally, the aqueous solubility of axitinib is pH dependent, with higher pH resulting in lower solubility.” (opens the source at this quote in a new tab)